Roberta Sciarra
A5059970909- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Viral-associated cancers and disorders
- Hepatitis C virus research
- CNS Lymphoma Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Immune Cell Function and Interaction
- Multiple and Secondary Primary Cancers
- Gastrointestinal Tumor Research and Treatment
- Acute Myeloid Leukemia Research
- CAR-T cell therapy research
- Cytomegalovirus and herpesvirus research
- Sarcoma Diagnosis and Treatment
- Toxoplasma gondii Research Studies
- Eosinophilic Disorders and Syndromes
- Herpesvirus Infections and Treatments
- Parathyroid Disorders and Treatments
- Acute Lymphoblastic Leukemia research
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Cutaneous lymphoproliferative disorders research
- HIV/AIDS drug development and treatment
- Neuroendocrine Tumor Research Advances
- Galectins and Cancer Biology
- Genetic and Kidney Cyst Diseases
- Cardiac tumors and thrombi
Policlinico San Matteo Fondazione
2013-2024
Istituti di Ricovero e Cura a Carattere Scientifico
2013-2024
University of Pavia
2014-2024
Policlinico Umberto I
2023
Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani
2023
Hepatitis C virus has been found to be associated with B-cell non-Hodgkin lymphomas, mostly marginal zone lymphomas and diffuse large lymphoma. Deregulation of signaling pathways involved in normal development (NOTCH pathway, NF-κB, BCR signaling) demonstrated splenic We studied mutations NOTCH pathway 46 patients hepatitis virus-positive lymphoma 64 unrelated HCV. NOTCH2 were detected 9 (20%) patients, NOTCH1 2 (4%). By contrast, only one HCV-negative had a or mutation. The frequency the...
Abstract Background International guidelines suggest hepatitis C virus (HCV) eradication by direct-acting antivirals (DAAs) after first-line immunochemotherapy (I-CT) in patients with HCV-positive diffuse large B-cell lymphoma (DLBCL), although limited experiences substantiate this recommendation. Moreover, only a few data concerning concurrent administration of DAAs I-CT have been reported. Subjects, Materials, and Methods We analyzed hematological virological outcome survival 47...
Letermovir (LTV), recently approved for the prophylaxis of human cytomegalovirus (HCMV) reactivation after hematopoietic stem cell transplantation (HSCT), has been shown to decrease rate infection in first months post-transplantation. The aim this study was evaluate impact LTV on immune reconstitution and late-onset infection. We studied HCMV HCMV-specific T 2 matched groups HSCT recipients, those treated with (n = 30; group) receiving preemptive therapy 31; PET group). analyzed rates...
The combination of rituximab, bendamustine, and low-dose cytarabine (R-BAC) has been studied in a phase 2 prospective multicenter study from Fondazione Italiana Linfomi (RBAC500). In 57 previously untreated elderly patients with mantle cell lymphoma (MCL), R-BAC was associated complete remission rate 91% 2-year progression-free survival (PFS) 81% (95% confidence interval [CI], 68-89). Here, we report the long-term outcomes, late toxicities, results minimal residual disease (MRD) evaluation....
Although patients with early-stage Hodgkin's lymphoma have a high rate of cure, portion these are resistant to or relapse after standard treatment. Current prognostic criteria based on clinical and laboratory parameters at diagnosis do not allow accurately identify the subset less favourable outcome. An increased number tumour-infiltrating macrophages was found be associated shortened survival in classic Lymphoma. The aim this study assess significance proportion CD68-positive infiltrating...
The gastrointestinal (GI) tract is the most common extranodal site of occurrence non-Hodgkin lymphomas. Most GI lymphomas are B-cell lineage, while T-cell less frequent. aim our retrospective study was to depict clinical–pathological profile a series patients affected by intestinal (ITCL) and possibly define hallmarks these neoplasms. A total 28 were included: 17 enteropathy-associated (EATL), 5 monomorphic epitheliotropic (MEITL), 3 indolent lymphoproliferative disorders (ITCLDGT), not...
Chronic hepatitis C virus (HCV) infection is related with an increased risk of non-Hodgkin lymphomas (NHL). In indolent subtypes, regression NHL was reported after HCV eradication antiviral therapy (AT). 2008 in Lombardy, a region Northern Italy, the "Rete Ematologica Lombarda" (REL, Hematology Network Lombardy-Lymphoma Workgroup) started prospective multicenter observational cohort study on associated infection, named "Registro Lombardo dei Linfomi HCV-positivi" ("Lombardy Registry...
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare entity whose neoplastic cells retain B-cell phenotype with expression of CD20. Radiotherapy recommended for favorable stage IA disease while other stages guidelines suggest therapeutic strategies similar to those used classic HL. The role rituximab, although quite widespread, not completely elucidated. We retrospectively analyzed baseline characteristics 308 consecutive patients NLPHL diagnosed in 19 Italian centers from 2000...
Summary Hepatitis C virus (HCV)‐associated diffuse large B‐cell lymphoma (DLBCL) displays peculiar clinicopathological characteristics, but its molecular landscape is not fully elucidated. In this study, we investigated the and features of 54 patients with HCV‐associated DLBCL. The median age was 71 years. An underlying marginal zone component detected in 14.8% cases. FISH analysis showed rearrangements involving BCL6 50.9% cases, MYC 11.3% BCL2 3.7%. Lymph2Cx‐based assay successful 38...
High-dose chemotherapy with autologous stem cell transplantation (ASCT) has been shown effective in the control of relapsed/refractory follicular lymphoma. We evaluate long-term outcome patients relapsed or refractory lymphoma treated ASCT vivo purged progenitors cells. report results a prospective multicenter phase 2 trial on 124 program anthracycline-based debulking chemotherapy, immunochemotherapy, mobilization PBSC followed by ASCT. Median age was 52 years; 14% had grade 3A histology....
The role of allogeneic stem cell transplantation (allo-SCT) in mantle lymphoma (MCL) is uncertain, even more the era bruton's tyrosine kinase inhibitors (BTKi) and chimeric antigen receptor T-cells. We retrospectively analyzed 55 patients who underwent allo-SCT for MCL relapsed or refractory (r/r) after rituximab high-dose cytarabine within MANTLE-FIRST project. With a median follow-up 3.7 years, non-relapse mortality (NRM), progression-free survival, overall survival were 23%, 53%, 56%,...
Introduction: Patients with mantle cell lymphoma (MCL) that fail induction treatment represent a difficult-to-treat population poor outcome, where no standard therapy exists. There is paucity of large-scale data in relapsed or refractory (r/r) MCL. Methods: MANTLE-FIRST, an international, retrospective study, evaluated outcomes patients MCL who had progressive disease first relapse when treated upfront high dose cytarabine (HDAC), followed by autologous stem transplantation if appropriate....
Background: Central nervous system (CNS) relapse of Mantle Cell Lymphoma (MCL) is a rare condition for which standard care has not been identified. Responses to conventional treatment CNS-MCL are poor and prognosis dismal, with median survival less than 6 months. Ibrutinib approved relapsed/refractory MCL; small series demonstrated its efficacy on CNS localization thanks the capability cross blood-brain barrier. Methods: We retrospectively analyzed multi-center consecutive patients (pts)...